CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Crizotinib Oral Capsule [Xalkori] +1 moredrug
Likely dose
Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03620643
NCT03620643Phase 2Completed
CompareCT.gov

Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Royal Marsden NHS Foundation Trust·interventional·Posted Aug 8, 2018·Updated Oct 30, 2025

In Brief

A Phase 2 clinical trial evaluating Crizotinib Oral Capsule [Xalkori] and Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic] for Lobular Breast Carcinoma and 3 related conditions. Completed, enrolled 33 participants across 5 sites.

Detailed Summary

The purpose of this study was to find out how effective the combination of crizotinib and fulvestrant was in shrinking lobular breast cancer tumours. The investigators also assessed the side effects of the combination of crizotinib tablets and fulvestrant injections. The side effects and the doses of crizotinib and fulvestrant had already been evaluated in large clinical trials, but this was the first time these two drugs had been combined together.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
CountriesUnited Kingdom
CollaboratorsPfizer, Breast Cancer Now

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 8, 2018
Enrollment StartMay 9, 2019
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.9 years ago

Interventions

Crizotinib Oral Capsule [Xalkori]drug

Crizotinib 250 mg Crizotinib 200mg

Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]drug

Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.